| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC65991 | Pamicogrel Featured | Pamicogrel (KBT3022) is a cyclooxygenase (COX) inhibitor. |
|
| DC65992 | 3,6,10,13,16-pentaoxa-1,8(1,4)-dibenzenacycloheptadecaphane-2,7,9,17-tetraone Featured |
|
|
| DC65993 | SKF 34874 Featured |
|
|
| DC65994 | Metronidazole Impurity 11 Featured |
|
|
| DC65995 | Bis(trans-cinnamic acid)anhydride Featured | Bis(trans-cinnamic acid)anhydride is a Parasite inhibitor tnat can be isolated from Cinnamomum zeylanicum and exhibits moderate activity against Plasmodium falciparum. |
|
| DC65996 | Tocainide HCl Featured |
|
|
| DC65997 | 2-isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione O,O-di(2-methylbenzoyl) dioxime Featured |
|
|
| DC65998 | WSB1 Degrader 1 Featured | WSB1 Degrader 1 is a poten and orally active WSB1 (WD repeat and SOCS box-containing 1) degrader. WSB1 Degrader 1 has anticancer metastatic effects. |
|
| DC65999 | Rotigotine(N 0437) Featured | (Rac)-Rotigotine (N-0437) is a racemate of Rotigotine. Rotigotine is a full agonist of?dopamine receptor, a partial agonist of the?5-HT1A receptor, and an antagonist of the?α2B-adrenergic receptor, with?Kis of 0.71?nM, 4-15?nM, and 83?nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor. |
|
| DC66000 | N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea Featured | N-[(1R)-4-[(Aminoiminomethyl)amino]-1-[[[(1R)-1-(4-hydroxyphenyl)ethyl]amino]carbonyl]butyl]-α-phenylbenzeneacetamide is an anticonvulsant agent with potential for the treatment of generalized tonic-clonic and partial seizures. |
|
| DC66001 | (E)-2-((5-nitrofuran-2-yl)methylene)hydrazine-1-carboxamide Featured |
|
|
| DC66002 | Retinoic acid, methyl ester Featured |
|
|
| DC66003 | 4-Keto all-trans-Retinoic Acid Methyl Ester Featured |
.png)
|
|
| DC66004 | NS3861 Featured | NS3861 is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding Ki values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively. |
|
| DC66005 | 2-(indolin-1-yl)-1-(4-(naphthalen-2-ylsulfonyl)piperazin-1-yl)ethan-1-one Featured |
|
|
| DC66006 | Protein kinase inhibitor 6 Featured | Protein kinase inhibitor 6 is a protein kinase inhibitor. |
|
| DC66007 | CDK9-IN-15 Featured | CDK9-IN-15 (compound 50) is a potent CDK9 inhibitor. |
|
| DC66008 | PARP-1-IN-2 Featured | PARP-1-IN-2 (compound 11g) is a potent and BBB-penetrated PARP1 inhibitor, with an IC50 of 149 nM. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis. |
|
| DC66009 | M4 mAChR agonist-1 Featured | M4 mAChR agonist-1 (compound 10a) is a potent M4 mAChR agonist with an EC50 >10 μM for human M4. |
|
| DC66010 | HIF1-IN-3 Featured | HIF1-IN-3 (compound F4) is a potent HIF1 inhibitor with an EC50 value of 0.9 μM. HIF1-IN-3 can be used for researching anticancer. |
|
| DC66011 | PARP1-IN-8 Featured | PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated PARP1 inhibitor, with an IC50 of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. |
|
| DC66012 | JAMM protein inhibitor 2 Featured | JAMM protein inhibitor 2 (compound 180) is a potent JAMM protease inhibitor with IC50s of 10 μM, 46 μM and 89 μM for thrombin, Rpn11 and MMP2, respectively. JAMM protein inhibitor 2 can be used for researching anticancer |
|
| DC66013 | (2-(1H-benzo[d][1,2,3]triazol-1-yl)acetyl)alanine Featured |
|
|
| DC66014 | (2-{[2-(2-fluorophenoxy)ethyl]sulfanyl}-1H-benzimidazol-1-yl)acetic acid Featured |
|
|
| DC66015 | 3-methyl-N-(3-(thiazolo[5,4-b]pyridin-2-yl)phenyl)butanamide Featured |
|
|
| DC66016 | Benzo[d]thiazol-2-ylmethyl ((2-fluorophenyl)sulfonyl)-L-alaninate Featured |
|
|
| DC66017 | WAY324208 Featured |
|
|
| DC66018 | Sirtuin modulator 7 Featured | Sirtuin modulator 7 is a sirtuin-modulating compound which may increase the lifespan of a cell, and may be used for research of diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and flushing which would benefit from increased mitochondrial activity. |
|
| DC66019 | WAY327059 Featured |
|
|
| DC66020 | 4-(((3-(4-Ethoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)thio)methyl)benzonitrile Featured |
|
